Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Change in Cash (2016 - 2025)

Historic Change in Cash for Ekso Bionics Holdings (EKSO) over the last 14 years, with Q3 2025 value amounting to -$2.5 million.

  • Ekso Bionics Holdings' Change in Cash fell 20469.46% to -$2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 23860.18%. This contributed to the annual value of -$2.1 million for FY2024, which is 8195.51% up from last year.
  • As of Q3 2025, Ekso Bionics Holdings' Change in Cash stood at -$2.5 million, which was down 20469.46% from -$2.8 million recorded in Q2 2025.
  • In the past 5 years, Ekso Bionics Holdings' Change in Cash registered a high of $36.7 million during Q1 2021, and its lowest value of -$8.7 million during Q4 2022.
  • Its 5-year average for Change in Cash is -$533684.2, with a median of -$2.8 million in 2025.
  • Examining YoY changes over the last 5 years, Ekso Bionics Holdings' Change in Cash showed a top increase of 165674.87% in 2021 and a maximum decrease of 29387.12% in 2021.
  • Over the past 5 years, Ekso Bionics Holdings' Change in Cash (Quarter) stood at -$3.0 million in 2021, then tumbled by 185.36% to -$8.7 million in 2022, then skyrocketed by 84.99% to -$1.3 million in 2023, then plummeted by 38.49% to -$1.8 million in 2024, then tumbled by 40.08% to -$2.5 million in 2025.
  • Its last three reported values are -$2.5 million in Q3 2025, -$2.8 million for Q2 2025, and $1.6 million during Q1 2025.